By combining expression analysis, survival analysis, and wet and dry research validation, a key pathway (hsa-miR-378-5p-APOC1/CEP55) of esophageal squamous cell carcinoma progression after neoadjuvant immunotherapy was identified. This evidence concerns the gene APOC1 and esophageal squamous cell carcinoma.